image-1-1024x578 Loberamisal improves functional recovery after an ischemic stroke

A new neuroprotective and neuroreparative treatment could expand therapeutic options after an acute ischemic stroke. The LAIS clinical trial has demonstrated that intravenous loberamisal, administered within the first ten days and initiated within 48 hours of symptom onset, significantly increases the proportion of patients achieving full functional recovery at 90 days. The results of the phase III trial, published in JAMA , provide evidence for a pharmacological strategy that complements reperfusion therapies, although further studies will be necessary before extending the results to populations other than the one studied.

A phase III trial with nearly a thousand patients

LAIS was a multicenter, randomized, double-blind, placebo-controlled trial conducted in 32 hospitals in China. It included 998 adults aged 18 to 80 years with acute ischemic stroke, a baseline score of 7 to 20 on the National Institutes of Health Stroke Scale (NIHSS), and no significant disability prior to the stroke.

Patients were randomly assigned 1:1 to intravenous loberamisal, 40 mg once daily for ten consecutive days, or placebo, in addition to standard treatment. The median time from symptom onset to drug administration was approximately 25 hours.

The main analysis population consisted of 997 participants: 502 treated with loberamisal and 495 with placebo. The median age was 64 years, and 33.7% were women. The median baseline NIHSS score was 8.

Greater functional recovery at 90 days

The primary efficacy criterion was achieving a score of 0 or 1 on the modified Rankin Scale (mRS) at 90 days, corresponding to absence of symptoms or significant functional disability.

This objective was achieved in 350 patients treated with loberamysal (69.7%) compared to 279 patients in the placebo group (56.3%). The absolute risk difference was 13.28%, with a 95% confidence interval between 7.24% and 19.32%. The relative risk was 1.24.

The results therefore indicate a statistically significant difference in favor of loberyssal in the primary endpoint. However, some secondary endpoints showed less conclusive results. For example, the proportion of patients with a Barthel Index of 95 or higher at 90 days was virtually identical between the two groups.

A dual action against neuronal damage

Loberamisal is a small molecule with a dual mechanism of action. It interferes with the interaction between PSD-95 and neuronal nitric oxide synthase, involved in excitotoxicity induced by pathological activation of NMDA receptors, and simultaneously acts as a positive allosteric modulator of α2-GABA A receptors .

This combination aims to limit ischemic neuronal damage and subsequently promote mechanisms related to neurogenesis, synaptogenesis, and neuronal plasticity. The compound has also shown experimental effects on stroke-associated neuroinflammation.

A safety profile similar to placebo

Adverse events were frequent in both groups, but without relevant differences: they appeared in 87.8% of patients treated with loberamisal and in 88.7% of those who received placebo.

Serious adverse events were reported in 8.6% and 10.7% of patients, respectively. All-cause mortality was 1.2% with loberamisal and 2.0% with placebo. The study was not designed to demonstrate differences in mortality.

The results need confirmation in other populations.

The trial has significant limitations for generalizability. All participating centers were located in China, the median baseline severity was relatively moderate, and patients who underwent endovascular thrombectomy were excluded. Only about 17% received intravenous thrombolysis.

Therefore, it still needs to be established whether the results are reproducible in more diverse populations, stroke patients of different severity, and current contexts of reperfusion by thrombectomy.

LAIS does, however, provide a relevant clinical signal: pharmacological intervention initiated up to 48 hours after stroke was associated with a significant improvement in full functional recovery. If independent studies confirm these results, loberamisal could represent a new complementary strategy for reducing disability after acute ischemic stroke.

share-medium Loberamisal improves functional recovery after an ischemic stroke